{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+inhaler&page=10", "query": { "intervention": "placebo inhaler", "page": 10 }, "page_size": 10 }, "pagination": { "page": 10, "page_size": 10, "total_count": 298, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+inhaler&page=11&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+inhaler&page=9&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T18:13:33.301Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01172821", "title": "Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "placebo", "type": "DRUG" }, { "name": "tiotropium Respimat® low dose", "type": "DRUG" }, { "name": "tiotropium Respimat® high dose", "type": "DRUG" }, { "name": "50 mcg salmeterol HFA MDI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1032, "start_date": "2010-08", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 18, "location_summary": "Los Angeles, California • Stockton, California • Centennial, Colorado + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stockton", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Panama City", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01172821" }, { "nct_id": "NCT02260492", "title": "Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "OT329 (combination of fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oriel Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 879, "start_date": "2014-09", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2017-06-15", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 47, "location_summary": "Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02260492" }, { "nct_id": "NCT07886554", "title": "LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sarcoidosis Associated Pulmonary Hypertension" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "LAM-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IRulya Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 60, "start_date": "2026-12", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07886554" }, { "nct_id": "NCT06018766", "title": "LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bronchiolitis Obliterans Syndrome", "Chronic Lung Allograft Dysfunction", "Lung Transplantation" ], "interventions": [ { "name": "LAM-001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Steven Hays, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2023-08-17", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06018766" }, { "nct_id": "NCT02604173", "title": "Altitude Sickness Prevention and Efficacy of Comparative Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Mountain Sickness" ], "interventions": [ { "name": "Budesonide", "type": "DRUG" }, { "name": "Acetazolamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 103, "start_date": "2016-08", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2018-12-12", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 1, "location_summary": "Bishop, California", "locations": [ { "city": "Bishop", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02604173" }, { "nct_id": "NCT01712516", "title": "A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "QVA149", "type": "DRUG" }, { "name": "QAB149", "type": "DRUG" }, { "name": "NVA237", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1001, "start_date": "2012-12", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-07-15", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 56, "location_summary": "Huntsville, Alabama • *See Various Dept.'s*, Arizona • Tempe, Arizona + 46 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "*See Various Dept.'s*", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Buena Park", "state": "California" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01712516" }, { "nct_id": "NCT03449511", "title": "Aromatherapy for Integrated Cancer Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Ginger aromatherapy", "type": "OTHER" }, { "name": "Orange aromatherapy", "type": "OTHER" }, { "name": "Lavender aromatherapy", "type": "OTHER" }, { "name": "Jojoba aromatherapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 83, "start_date": "2018-04-11", "completion_date": "2023-01-30", "has_results": false, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 2, "location_summary": "Buffalo, New York • Rochester, New York", "locations": [ { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03449511" }, { "nct_id": "NCT01854658", "title": "Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease (COPD)" ], "interventions": [ { "name": "GFF MDI (PT003)", "type": "DRUG" }, { "name": "GP MDI (PT001)", "type": "DRUG" }, { "name": "FF MDI (PT005)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pearl Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 1615, "start_date": "2013-07", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 113, "location_summary": "Birmingham, Alabama • Florence, Alabama • Jasper, Alabama + 110 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Florence", "state": "Alabama" }, { "city": "Jasper", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01854658" }, { "nct_id": "NCT06968845", "title": "A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Pulmonary Fibrosis (IPF)" ], "interventions": [ { "name": "LTI-03", "type": "DRUG" }, { "name": "Dry Powder Inhaler", "type": "DEVICE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Rein Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 120, "start_date": "2026-02-02", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-11-12", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06968845" }, { "nct_id": "NCT05819541", "title": "Treating Exacerbations of Asthma With Oral Montelukast in Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Status Asthmaticus" ], "interventions": [ { "name": "Montelukast Oral Granules", "type": "DRUG" }, { "name": "Albuterol", "type": "DRUG" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "4 Years to 12 Years" }, "enrollment_count": 90, "start_date": "2023-10-20", "completion_date": "2026-03-26", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-15T18:13:33.301Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05819541" } ] }